RECOMMENDATION REITERATED WANG LABS &lt;WANB> Analyst Thomas McCrann Merrill Lynch reiterated "buy" recommendation Wang Laboratories Inc, noting successful cost cutting campaign reduce earnings loss expected quarter ending March. Wang actively traded stock American Stock Exchange, rising 3/4 16-5/8. McCrann "Wang bit ahead expected cost reductions, result, odds increased loss quarter expected." McCrann expects Wang report break earnings share small loss share quarter. year, however, company report loss 50 cts share compared earnings 35 cts share year ago.